Stockscreener 앱 받기
9.56
0.31%
0.03
시간 외 거래:
9.57
0.010
+0.10%
전일 마감가:
$9.53
열려 있는:
$9.69
하루 거래량:
334.17K
Relative Volume:
1.45
시가총액:
$476.43M
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-3.5018
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
-6.64%
1개월 성능:
-2.15%
6개월 성능:
-14.18%
1년 성능:
-37.31%
1일 변동 폭
$9.37
$9.8458
1주일 범위
$8.98
$10.75
52주 변동 폭
$8.58
$16.91
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
9.56 | 476.43M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results - MSN
When the Price of (MLYS) Talks, People Listen - Stock Traders Daily
Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
The Goldman Sachs Group Has Lowered Expectations for Mineralys Therapeutics (NASDAQ:MLYS) Stock Price - Defense World
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Defense World
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down Following Analyst Downgrade - MarketBeat
Mineralys Therapeutics' (MLYS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2024 Earnings Call Transcript - MSN
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down on Analyst Downgrade - Defense World
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat - MSN
Mineralys Therapeutics Highlights Positive Earnings Call - TipRanks
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Promising Outlook for Mineralys Therapeutics: Buy Rating Affirmed on Lorundrostat’s Potential - TipRanks
Windtree Therapeutics Highlights Promising Phase 2b Results for Istaroxime - MyChesCo
Earnings call transcript: Mineralys Therapeutics Q4 2024 misses EPS forecast By Investing.com - Investing.com Australia
Mineralys Therapeutics Reports 2024 Earnings and Trial Progress - TipRanks
Mineralys outlines pivotal trial timelines for lorundrostat in hypertension - MSN
Earnings call transcript: Mineralys Therapeutics Q4 2024 misses EPS forecast - Investing.com India
Mineralys Therapeutics : Corporate Overview February 2025 - Marketscreener.com
Promising Growth Ahead: Mineralys Therapeutics Positioned for Success with Robust Financials and Key Hypertension Study Results - TipRanks
Mineralys Therapeutics Inc. (MLYS) reports earnings - Quartz
Mineralys Therapeutics, Inc. SEC 10-K Report - TradingView
MINERALYS THERAPEUTICS Earnings Results: $MLYS Reports Quarterly Earnings - Nasdaq
Mineralys Therapeutics Announces Clinical Trial Updates and Fourth Quarter 2024 Financial Results - Nasdaq
Mineralys Financial Results Reveal Strong Pipeline Progress: 3 Major Clinical Readouts Coming in 2025 - StockTitan
Mineralys Therapeutics (MLYS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients - MyChesCo
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Acquired by Jennison Associates LLC - MarketBeat
Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Stock Has Dropped -21.18% Over The Month – Is There Room For Growth? - Marketing Sentinel
Mineralys Therapeutics Inc (NASDAQ: MLYS): Can The Stock Still Lose Despite An -20.31% YTD Loss? - Marketing Sentinel
Mineralys Therapeutics (MLYS) to Release Earnings on Wednesday - Defense World
Allarity Therapeutics advances ovarian cancer drug trial - MSN
Long Term Trading Analysis for (MLYS) - Stock Traders Daily
Clinical Trials News Live Feed - StockTitan
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by SG Americas Securities LLC - Defense World
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Mineralys Therapeutics, Inc.(MLYS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Hypertension Drug Developer Mineralys Therapeutics Announces Critical Q4 Earnings Date - StockTitan
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 - Marketscreener.com
Mineralys Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 - Nasdaq
Mineralys Therapeutics to Announce Fourth Quarter and Full - GlobeNewswire
Mineralys Completes Enrollment In Phase 2 Explore-CKD Trial Of Lorundrostat For Hypertension - Nasdaq
Mineralys completes enrollment for hypertension drug trial - MSN
Mineralys Completes Enrollment in Mid-Stage Hypertension Trial -February 04, 2025 at 11:43 am EST - Marketscreener.com
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):